KR890701736A - 과산화물 분자변위보효소의 포합체 - Google Patents

과산화물 분자변위보효소의 포합체

Info

Publication number
KR890701736A
KR890701736A KR1019890700575A KR890700575A KR890701736A KR 890701736 A KR890701736 A KR 890701736A KR 1019890700575 A KR1019890700575 A KR 1019890700575A KR 890700575 A KR890700575 A KR 890700575A KR 890701736 A KR890701736 A KR 890701736A
Authority
KR
South Korea
Prior art keywords
conjugate
polyethylene glycol
glycol
peroxide
pharmaceutical composition
Prior art date
Application number
KR1019890700575A
Other languages
English (en)
Other versions
KR920001426B1 (ko
Inventor
사이퍼 마크
소맥 랄프
윌리암스 엘.데이비드
Original Assignee
원본미기재
디디아이파마슈티칼스인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 디디아이파마슈티칼스인코포레이티드 filed Critical 원본미기재
Publication of KR890701736A publication Critical patent/KR890701736A/ko
Application granted granted Critical
Publication of KR920001426B1 publication Critical patent/KR920001426B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/089—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

과산화물 분자변위보효소의 포합체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 폴리에틸렌글리콜이나 폴리에틸렌 폴리프로필렌 글리콜 공중합체 잔기같은 그중에 상술된 글리콜이 표준물질을 PEG로하여 HPLC로 측정하였을 때 평균 분자량이 대략 40,000-1,000,000인 것으로 말단이 C1∼4-알킬이나 C1∼4-알콕시기로 치환된 것이나 미치환된 것인 폴리알킬렌 글리콜에 연결시약으로 연결된 과산화물 분자변위 보효소의 수용성인, 실제적으로는 비 면역적인 포합체.
  2. 제1항에 있어서, HPLC에 의해 측정된 평균 분자량이 대략 40,000-200,000인 폴리에틸렌 글리콜인 폴리알킬렌 글리콜로 된 포합체.
  3. 제2항에 있어서, 평균 분자량이 대략 50,000-150,000인 폴리에틸렌 글리콜인 폴리 알킬렌 글리콜로된 포합체.
  4. 제3항에 있어서, 2개에서 8개의 폴리에틸렌글리콜기가 과산화물 분자변위 보효소 분자를 함유하는 구리와 아연에 각각 연결되어 있는 포합체.
  5. 제4항에 있어서, 2개 내지 6개의 폴리에틸렌글리콜기가 각각의 과산화물 분자변위 보효소 분자에 연결되어 있는 포합체.
  6. 제5항에 있어서, 폴리에틸렌글리콜이 이소프로폭시 폴리에틸렌 글리콜인 포합체.
  7. 제1항에 있어서, 폴리에틸렌 글리콜의 말단기가 과산화물 분자변위 보효소 리신의 말단 아미노기에 Co결합으로 부착되어 있는 포합체.
  8. 과산화물 분자변위 보효소의 치료효과에 유효한 제1항의 포합체를 함유하고 있는 약제학적 구성.
  9. 항염효과에 유효한 양의 포합체를 함유하고 있는 제8항에 따른 약제학적 구성.
  10. 산소독성을 경감시키는데 효과적인 양의 포합체를 함유하는 제8항에 따른 약제학적 구성.
  11. 재관류 상처를 방지하는데 효과적인 양의 포합체를 함유하는 제8항에 따른 약제학적 구성.
    ※ 참고사항：최초출원 내용에 의하여 공개하는 것임.
KR1019890700575A 1987-08-03 1988-07-29 과산화물 분자변위 보효소의 포합체 KR920001426B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81009 1979-10-01
US8100987A 1987-08-03 1987-08-03
US081.009 1987-08-03
PCT/US1988/002530 WO1989001033A1 (en) 1987-08-03 1988-07-29 Conjugates of superoxide dismutase

Publications (2)

Publication Number Publication Date
KR890701736A true KR890701736A (ko) 1989-12-21
KR920001426B1 KR920001426B1 (ko) 1992-02-13

Family

ID=22161332

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890700575A KR920001426B1 (ko) 1987-08-03 1988-07-29 과산화물 분자변위 보효소의 포합체

Country Status (17)

Country Link
EP (1) EP0377613B1 (ko)
JP (1) JP2515389B2 (ko)
KR (1) KR920001426B1 (ko)
CN (1) CN1020458C (ko)
AU (1) AU608901B2 (ko)
CA (1) CA1309046C (ko)
DE (1) DE3876997T2 (ko)
DK (1) DK160842C (ko)
ES (1) ES2007536A6 (ko)
HU (1) HU203783B (ko)
IE (1) IE64284B1 (ko)
IL (1) IL87177A (ko)
NZ (1) NZ225481A (ko)
PH (1) PH27225A (ko)
RU (1) RU1776275C (ko)
WO (1) WO1989001033A1 (ko)
ZA (1) ZA885249B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470128B2 (en) † 1989-04-19 2003-08-13 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5109118A (en) * 1989-07-06 1992-04-28 Yutaka Mizushima Modified biologically active proteins
GB8919661D0 (en) * 1989-08-31 1989-10-11 Univ Alberta Superoxide dismutase-catalase conjugates
US5772996A (en) * 1990-08-03 1998-06-30 Public Health Laboratory Service Board Pharmaceutical compositions containing superoxide dismutase from Bacillus Stearothermophilus and Bacillus Caldotenax
EP0598037A1 (en) * 1991-08-05 1994-05-25 Sanofi Buffered formulation of peg-sod
FR2687681B1 (fr) * 1992-02-20 1995-10-13 Transgene Sa Conjugues polyethyleneglycol-hirudine, leur procede de preparation et leur emploi pour le traitement des thromboses.
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5516703A (en) * 1993-08-20 1996-05-14 The University Of Utah Coating of hydrophobic surfaces to render them protein resistant while permitting covalent attachment of specific ligands
US6284503B1 (en) 1993-08-20 2001-09-04 University Of Utah Research Foundation Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces
AU768765B2 (en) * 1998-06-23 2004-01-08 Novozymes A/S A polypeptide-polymer conjugate
US6638526B1 (en) 1998-06-23 2003-10-28 Novozymes A/S Polypeptides conjugated to copolymers of ethylene oxide and propylene oxide to reduce allergenicity
WO2000004138A1 (en) * 1998-07-17 2000-01-27 Novozymes A/S A polypeptide-polymer conjugate with improved wash performance
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EA008866B1 (ru) 2002-12-26 2007-08-31 Маунтин Вью Фамэсьютикэлс, Инк. ПОЛИМЕРНЫЙ КОНЪЮГАТ МОДИФИКАЦИЙ ИНТЕРФЕРОНА-β, ФАРМАЦЕВТИЧЕСКИЕ ПРОДУКТЫ НА ЕГО ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
BRPI0411160A (pt) * 2003-05-12 2006-07-11 Affymax Inc novos compostos modificados com poli(glicol etilênico) e usos dos mesmos
CN108445106A (zh) * 2018-04-11 2018-08-24 南京明捷生物医药检测有限公司 一种药物中消泡剂聚丙二醇残留的检测方法
CN108864309B (zh) * 2018-07-26 2021-07-13 广州暨南大学医药生物技术研究开发中心有限公司 重组人sod-生长因子融合蛋白、其制备方法及其应用
CN109112119B (zh) * 2018-08-28 2022-04-26 佛山科学技术学院 经化学修饰的鸭血sod制剂的制备方法
CN117551625B (zh) * 2024-01-12 2024-03-08 山东爱维德生物科技有限公司 一种用于木立芦荟sod胶的聚乙二醇二胺-海藻酸改性sod酶及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74177A (en) * 1984-02-03 1989-09-10 Abbott Lab Stabilized enzyme conjugate composition containing a calcium salt and a polyethylene glycol
GB8430253D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ

Also Published As

Publication number Publication date
EP0377613A1 (en) 1990-07-18
NZ225481A (en) 1990-11-27
JP2515389B2 (ja) 1996-07-10
HU203783B (en) 1991-09-30
PH27225A (en) 1993-05-04
DE3876997D1 (de) 1993-02-04
IL87177A0 (en) 1988-12-30
ES2007536A6 (es) 1989-06-16
HUT52816A (en) 1990-08-28
DK160842B (da) 1991-04-22
DE3876997T2 (de) 1993-04-29
JPH02504341A (ja) 1990-12-13
WO1989001033A1 (en) 1989-02-09
CA1309046C (en) 1992-10-20
AU2326888A (en) 1989-03-01
DK160842C (da) 1991-10-14
CN1020458C (zh) 1993-05-05
RU1776275C (ru) 1992-11-15
ZA885249B (en) 1989-04-26
EP0377613B1 (en) 1992-12-23
IE64284B1 (en) 1995-07-26
IL87177A (en) 1992-08-18
CN1031088A (zh) 1989-02-15
KR920001426B1 (ko) 1992-02-13
IE882206L (en) 1989-02-03
DK392789D0 (da) 1989-08-10
AU608901B2 (en) 1991-04-18
DK392789A (da) 1989-08-10

Similar Documents

Publication Publication Date Title
KR890701736A (ko) 과산화물 분자변위보효소의 포합체
AR008378A1 (es) Conjudados de interferon
FI853926A0 (fi) Stabiliserade piroxikaminjektionsloesningar.
IT1282686B1 (it) Composti in grado di ridurre la tossicita' da farmaci
FR2673537B1 (fr) Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
BR0100046A (pt) Copolìmeros reticulados solúveis em água ou intumescìveis em água
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
PT1157037E (pt) Conjugados de gcsf
ATE117351T1 (de) Wasserbeständige tintenzusammensetzung.
BR9808928A (pt) Complexo molecular e liberação controlada dealfa hidroxiácidos
EA199600024A2 (ru) Жидкая стабильная фармацевтическая композиция, содержащая уратоксидазу и лиофилизат для ее получения
SE8404065D0 (sv) Novel biologically active compounds
IE39627L (en) Hair and skin protection
DE60001568D1 (de) Benzopyrane, anneliert via c7-c8 mit einem aromatischen heterocyclus und diese enthaltende zubereitungen und (co)polymer matrices
KR900700124A (ko) 흑색종 치료용 il-2 및 dtic의 치료 조성물
DE3773440D1 (de) Pharmazeutische zusammensetzungen fuer suppositorien.
FR2707638B1 (fr) Nouveaux dérivés d'amino-acides, leurs procédés de préparation et leur application thérapeutique.
CA2047802A1 (en) Pharmaceutical compositions
KR100572603B1 (ko) 항종양제
HU9503047D0 (en) 5,6-dihydroxi-indole polymers, process for their preparation and compositions containing them
KR870001832A (ko) 비경구용 페니토인 조성물
DK0616813T3 (da) Polymer antitumorsammensætning med mitoxantron
IT1147330B (it) Medicamento,o preparato farmaceutico,ad azione citostatica
FR2768145B1 (fr) Nouveaux composes derives d'acide alkylene diamine di- ou tri-acetique, leur procede de preparation, leur utilisation dans des compositions cosmetiques et pharmaceutiques, et compositions les comprenant
FR2770777B1 (fr) Composition synergique associant de l'acs et/ou de l'adn a de l'hydroxyproline ainsi que leurs applications en nutritherapie et en cosmetologie

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070208

Year of fee payment: 16

LAPS Lapse due to unpaid annual fee